VINORELBINE INJECTION, USP SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

VINORELBINE (VINORELBINE TARTRATE)

可用日期:

GENERIC MEDICAL PARTNERS INC

ATC代码:

L01CA04

INN（国际名称）:

VINORELBINE

剂量:

10MG

药物剂型:

SOLUTION

组成:

VINORELBINE (VINORELBINE TARTRATE) 10MG

给药途径:

INTRAVENOUS

每包单位数:

1ML/5ML

处方类型:

Prescription

治疗领域:

ANTINEOPLASTIC AGENTS

產品總結:

Active ingredient group (AIG) number: 0126071001; AHFS:

授权状态:

APPROVED

授权日期:

2014-09-04

产品特点

_Page 1 of 32_
PRODUCT MONOGRAPH
PR
VINORELBINE INJECTION, USP
(10 mg/1 mL and 50 mg/5 mL)
10 mg/mL vinorelbine (as vinorelbine tartrate)
Sterile Solution for Injection
Concentrate: Solution Must Be Diluted Before Use
Antineoplastic Agent
Generic Medical Partners Inc.
251 Consumers Road, Suite 1200
Date of Preparation:
Toronto, Ontario
September 03, 2014
M2J 4R3
Control # 163682
_Page 2 of 32_
PRODUCT MONOGRAPH
PR
VINORELBINE INJECTION, USP
(10 mg/1 mL and 50 mg/5 mL)
10 mg/mL vinorelbine (as vinorelbine tartrate)
Sterile Solution for Injection
Concentrate: Solution Must Be Diluted Before Use THERAPEUTIC
CLASSIFICATION
Antineoplastic Agent
CAUTION
VINORELBINE INJECTION, USP IS A CYTOTOXIC DRUG AND SHOULD BE USED
ONLY BY PHYSICIANS EXPERIENCED WITH CANCER CHEMOTHERAPEUTIC
DRUGS.
BLOOD
COUNTS
SHOULD
BE
TAKEN
PRIOR
TO
EACH
DOSE.
THE
DOSAGE
SHOULD
BE
REDUCED
OR
THE
DRUG
DISCONTINUED
UPON
EVIDENCE OF ABNORMAL DEPRESSION OF THE BONE MARROW.
THIS PREPARATION IS FOR INTRAVENOUS ADMINISTRATION ONLY. INTRATHECAL
ADMINISTRATION OF OTHER
VINCA ALKALOIDS HAS RESULTED IN DEATH. SYRINGES CONTAINING THIS
PRODUCT SHOULD BE LABELED
"WARNING - FOR INTRAVENOUS USE ONLY. FATAL IF GIVEN INTRATHECALLY”.
CLINICAL PHARMACOLOGY
Vinorelbine tartrate is a novel vinca alkaloid which interferes with
microtubule assembly. Vinca
alkaloids are structurally similar compounds comprising two
multiringed units, vindoline and
catharanthine. Vinorelbine tartrate is a vinca alkaloid in which the
catharanthine unit is the site of
structural modification. This structural change imparts unique
pharmacologic properties which
may translate into clinical benefits for patients with various
malignancies. The antitumor activity
of vinorelbine tartrate is thought to be due primarily to inhibition
of mitosis at metaphase through
its interaction with tubulin. Vinorelbine tartrate may also interfere
with amino acid, cyclic AMP
and
glutathione
metabolism;
calmodulin-dependent
Ca
++
-transport
ATPase
activity;
cellular
_Page 3 of 32_
respiration; and nucleic acid a